sc002 profile

SC002: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	131954443
MeSH ID	M0393124

Synonym
sc-002
rovalpituzumab-tesirin
rovalpituzumab tesirine
rovalpituzumab tesirine [usan:inn:who-dd]
1613313-09-9
sc002
sc0002
rovalpituzumab tesirine [inn]
rovalpituzumab tesirine [usan:inn]
rovalpituzumab tesirine [who-dd]
unii-p256hb60ff
rova-t
p256hb60ff ,

Excerpt	Reference
" The most common treatment-related adverse events (≥25% of patients, all grades) were platelet count decreased, pleural effusion, peripheral edema, aspartate aminotransferase increased, white blood cell count decreased, neutrophil count decreased, alanine aminotransferase increased, hypoalbuminaemia, anemia and decreased appetite."	( Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. Akamatsu, H; Fujiwara, Y; Kanda, S; Kirita, K; Kosloski, MP; Nakagawa, K; Okamoto, I; Okubo, S; Scripture, C; Shintani, M; Takeda, M; Tamura, T; Tanaka, K; Teraoka, S; Udagawa, H; Yasuda, I, 2019)
" The most common adverse events (AE) were fatigue, photosensitivity reaction, and pleural effusion."	( Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. Besse, B; Carbone, DP; Dowlati, A; Farago, AF; Glisson, BS; Govindan, R; Greillier, L; Hann, CL; Lally, S; Le Moulec, S; Morgensztern, D; Ready, N; Rudin, CM; Santana-Davila, R; Wolf, J; Yalamanchili, S, 2019)
" The combination was tolerated, with the most common treatment-emergent adverse events (in >30%) being pleural effusion, fatigue, and cough."	( Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. Afar, DE; Alanko, T; Calvo, E; Cassier, PA; Englert, S; Gao, B; Gazzah, A; Italiano, A; Komarnitsky, P; Kondo, S; Lambert, S; Miguel, M; Millward, M; Moreno, V; Parikh, A; Peltola, K; Prenen, H; Rottey, S; Seto, T; Spira, A; Toyozawa, R; Vosganian, G; Warburton, L; Yoh, K, 2021)

Excerpt	Reference
" Cohort 2 received the same dosage of Rova-T as cohort 1 plus 1 mg/kg nivolumab (four 3-wk cycles) and 1 mg/kg ipilimumab (beginning week 4)."	( A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. Besse, B; Blot, V; Curigliano, G; Greillier, L; Johnson, ML; Lally, S; Leal, T; Lehman, J; Maag, D; Malhotra, J; Morgensztern, D; Nikolinakos, P; Patel, JD; Ready, N; Robinet, G; Valenzuela, R; Wrangle, JM, 2021)
"A total of 26 patients were dosed (cohort 3: 14; cohorts 1, 2, and 4 combined: 12)."	( A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC. Burns, TF; Camidge, DR; Chen, C; Dowlati, A; Hann, CL; Koch, MM; Komarnitsky, P; Ludwig, C; Morgensztern, D; Nimeiri, H; Patel, M; Ward, PJ, 2021)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	17 (56.67)	24.3611
2020's	13 (43.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	10 (32.26%)	5.53%
Reviews	8 (25.81%)	6.00%
Case Studies	2 (6.45%)	4.05%
Observational	0 (0.00%)	0.25%
Other	11 (35.48%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
temozolomide [no description available]	3.69	2	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
platinum Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.	3.7	1	1	elemental platinum; nickel group element atom; platinum group metal atom
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.21	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	4.04	2	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	4.04	2	1	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
irinotecan [no description available]	2.21	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
cephalosporin c cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.	4.83	2	1	cephalosporin	fungal metabolite
carboplatin [no description available]	4.04	2	1
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	2.21	1	0	one-carbon compound; thioureas; ureas	antioxidant; chromophore
amrubicin amrubicin: structure in first source; a 9-amino-anthracycline antibiotic. amrubicin : A synthetic anthracycline antibiotic with molecular formula C25H25NO9. A specific inhibitor of topoisomerase II, it is used (particularly as the hydrochloride salt) in the treatment of cancer, especially lung cancer, where it is a prodrug for the active metabolite, ambrucinol.	2.21	1	0	anthracycline antibiotic; methyl ketone; primary amino compound; quinone; tetracenes	antineoplastic agent; prodrug; topoisomerase II inhibitor
clobetasol Clobetasol: A derivative of PREDNISOLONE with high glucocorticoid activity and low mineralocorticoid activity. Absorbed through the skin faster than FLUOCINONIDE, it is used topically in treatment of PSORIASIS but may cause marked adrenocortical suppression.. clobetasol : A 3-oxo-Delta(1),Delta(4)-steroid that is 16beta-methylpregna-1,4-diene-3,20-dione bearing hydroxy groups at the 11beta and 17alpha positions, fluorine at position 9, and a chlorine substituent at position 21. It is used as its 17alpha-propionate ester to treat various skin disorders, including exzema and psoriasis.	2.17	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; fluorinated steroid; glucocorticoid; tertiary alpha-hydroxy ketone	anti-inflammatory drug; SMO receptor agonist
mp470 [no description available]	2.21	1	0	N-arylpiperazine
cblc137 CBLC137: a FACT histone chaperone inhibitor with antineoplastic activity; structure in first source. CBL0137 : A member of the class of carbazoles that is 9H-carbazole which is substituted by acetyl groups at positions 3 and 6, and by a 2-isopropylethyl group on the nitrogen atom (position 9). It is a modulator of histone chaperone FACT (FAcilitates Chromatin Transcription) - interaction of CBL0137 with the FACT complex results in simultaneous NF-kappa beta suppression, Heat Shock Transcription Factor 1 (HSF1) suppression and p53 activation - and shows antitumour effects in animal models of various cancers.	2.31	1	0	aromatic ketone; carbazoles; methyl ketone; secondary amino compound; tertiary amino compound	antineoplastic agent; apoptosis inducer; NF-kappaB inhibitor; p53 activator
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	3.27	1	0	dacarbazine

Condition	Relationship Strength	Studies	Trials
Carcinoma, Small Cell Lung [description not available]	14.89	42	10
Cancer of Lung [description not available]	15.01	44	12
Cells, Neoplasm Circulating [description not available]	4.07	2	1
Lung Neoplasms Tumors or cancer of the LUNG.	15.01	44	12
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	14.89	42	10
Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)	4.02	9	0
Recrudescence [description not available]	4.51	1	1
Metastase [description not available]	4.51	1	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	4.51	1	1
Local Neoplasm Recurrence [description not available]	8.5	7	5
Spider Veins [description not available]	2.25	1	0
Telangiectasis Permanent dilation of preexisting blood vessels (CAPILLARIES; ARTERIOLES; VENULES) creating small focal red lesions, most commonly in the skin or mucous membranes. It is characterized by the prominence of skin blood vessels, such as vascular spiders.	2.25	1	0
Cardiac Toxicity [description not available]	3.7	1	1
Electrocardiogram QT Prolonged [description not available]	3.7	1	1
Long QT Syndrome A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.	3.7	1	1
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	3.7	1	1
Benign Neoplasms [description not available]	3.23	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.23	1	0
Invasiveness, Neoplasm [description not available]	3.06	1	0
Dermatitis, Contact, Phototoxic [description not available]	2.17	1	0
Dermatitis Medicamentosa [description not available]	2.17	1	0
Hepatocellular Carcinoma [description not available]	2.17	1	0
Cancer of Liver [description not available]	2.59	2	0
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.17	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.59	2	0
Glial Cell Tumors [description not available]	2.21	1	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.21	1	0
B-Cell Lymphoma [description not available]	3.09	1	0
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	3.09	1	0
Disease Exacerbation [description not available]	2.21	1	0
Cancer of Prostate [description not available]	3.59	1	1
Androgen-Independent Prostatic Cancer [description not available]	3.59	1	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	3.59	1	1
Carcinoma, Neuroendocrine A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)	6.58	3	3
Prostatic Neoplasms, Castration-Resistant Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.	3.59	1	1
Carcinoma, Non-Small Cell Lung [description not available]	2.15	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.15	1	0
Carcinoma, Large Cell A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)	5.93	2	2

sc002

Description

Cross-References

Synonyms (13)

Toxicity

Dosage Studied

Research

Studies (30)

Study Types

sc002

Description

Cross-References

Synonyms (13)

Toxicity

Dosage Studied

Research

Studies (30)

Study Types

Related Drugs (14)

Related Conditions (38)